Quote:
Originally posted by Greedy,Greedy,Greedy
...
(2) regulation: there are foreign countries where regulators simply won't permit a drug to be priced very high, and you get a choice of going into the jurisdiction with a low price or not going in at all. In Canada, for example, the price of drugs that are still under patent is heavily regulated.
(3) culture: here, there is often a premium for the latest thing. In other countries, premium pricing more often goes to proven drugs with a high clinical efficacy. Note that the US often prices generics below what those in other countries will pay.
...
Bottom line: if we do find some ways to reduce pricing here, we'll probably drive prices up elsewhere since then other countries will have to help cover the R&D nut. Right now, I'm told pharmas often budget drug development based almost exclusively on the US market and their ability to recover the R&D from our market.
|
Re: 2. Did the regulators take the position that the drugs won't be allowed at all in their jurisdictions, or just that the drugs will be provided in an extra-legal manner? This is really my fundamental question here... did someone threaten to violate patents of the U.S. pharamaceutical industry as a nation?
Re: 3. Interesting (your comment on generics). Hadn't heard that before.
Re: Bottom line. Exactly. I'm told the same thing, and it offends me to no end that the risk/reward tends to overwhelmingly favor Amermican risk-taking companies, but at the expense of American consumers. Some of these countries have per-capita incomes almost equal to ours. It sounds entirely like a free-rider/strong-arm theft problem.
Hello
